Nicotinic Acid (Niacin) Receptor Agonists: Will They Be Useful Therapeutic Agents?

American Journal of Cardiology

Volumn 100, Issue 11 SUPPL. 1, 2007, Pages

  Kamanna, Vaijinath S ^a   Kashyap, Moti L ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; APOLIPOPROTEIN B; DIACYLGLYCEROL ACYLTRANSFERASE; FATTY ACID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PROSTAGLANDIN D2;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CATABOLISM; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LANGERHANS CELL; LIPOLYSIS; LIVER CELL; MACROPHAGE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ADIPOCYTES; DIACYLGLYCEROL O-ACYLTRANSFERASE; HEPATOCYTES; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; NICOTINIC AGONISTS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC;

EID: 36448978498     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.09.080     Document Type: Article

References (60)

1. Altschul R., Hoffer A., and Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 54 (1955) 558-559
2. Meyers C.D., Kamanna V.S., and Kashyap M.L. Niacin therapy in atherosclerosis. Curr Opin Lipidol 15 (2004) 659-665
3. th anniversary review. J Intern Med 258 (2005) 94-114
4. Ganji S.H., Zhang L.-H., Kamanna V.S., and Kashyap M.L. Effect of niacin on lipoproteins and atherosclerosis. Future Lipidol 1 (2006) 549-557
5. Morgan J.M., Capuzzi D.M., and Baksh R.I. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91 (2003) 1432-1436
6. Zambon A., Hokanson J.E., Brown B.G., and Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99 (1999) 1959-1964
7. Backes J.M., and Gibson C.A. Effect of lipid lowering drug therapy on small-dense low-density lipoprotein. Ann Pharmacother 39 (2005) 523-526
8. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., and Watkins M.L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88 (2001) 270-274
9. 3 in hyperlipoproteinaemia. J Intern Med 228 (1990) 151-157
10. Shepherd J., Betteridge J., Van Gaal L., and European Consensus Panel. Nicotinic acid in the management of dyslipidemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 21 (2005) 665-682
11. Sakai T., Kamanna V.S., and Kashyap M.L. Niacin but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 21 (2001) 1783-1789
12. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., and Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
13. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. Circulation 110 (2004) 3512-3517
14. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164 (2004) 697-705
15. Cefali E.A., Simmons P.D., Stanek E.J., and Shamp T.R. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther 44 (2006) 633-640
16. Lorenzen A., Stannek C., Lang H., Andrianov V., Kalvinsh I., and Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 59 (2001) 349-357
17. Aktories K., Jakobs K.H., and Schultz G. Nicotinic acid inhibits adipocyte cyclase in a hormone-like manner. FEBS Lett 115 (1980) 11-14
18. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., and Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9 (2003) 352-355
19. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eiler M., Ignar D.M., Murdock P.R., Steplewski K., Green A., et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278 (2003) 9869-9874
20. Soga T., Kamohara M., Takasaki J., Matsumoto S.-H., Saito T., Ohishi T., Hiyama H., Matsuo A., Matsushime H., and Furuichi K. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 303 (2003) 364-369
21. Zellner C., Pullinger C.R., Aouizerat B.E., Frost P.H., Kwok P.Y., Malloy M.J., and Kane J.P. Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors. Hum Mutat 25 (2005) 18-21
22. Lovisolo P.P., Briatico-Vangosa G., Orsini G., Ronchi R., and Angelucci R. Pharmacological profile of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) 1(II). Anti-lipolytic and blood lipid lowering activity. Pharmacol Res Commun 13 (1981) 163-174
23. Crepaldi G., Avogaro P., Descovich G.C., Di Perri T., Postiglione A., Sirtori C.R., Strano A., Ventura S., and Musatti L. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia: results of a multicenter trial. Atherosclerosis 70 (1988) 115-121
24. Cayen M.N., Kallai-Sanfacon M.A., Dubec J., Greselin E., and Dvornik D. Evaluation of the lipid-lowering activity of AY-25712 in rats. Atherosclerosis 45 (1982) 267-279
25. Hunninghake D.B., Edwards D.G., Sopko G.S., and Tosiello R.L. Controlled trial of acifran in type II hyperlipoproteinemia. Clin Pharmacol Ther 38 (1985) 313-317
26. Tunaru S., Lattig J., Kero J., Krause G., and Offermanns S. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol 68 (2005) 1271-1280
27. Ginsberg H.N. Synthesis and secretion of apolipoprotein B from cultured liver cells. Curr Opin Lipidol 6 (1995) 275-280
28. Davis R.A. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta 1440 (1999) 1-31
29. Grundy S.M., Mok H.Y.I., Zech L., and Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 22 (1981) 24-36
30. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler Thromb Vasc Biol 19 (1999) 1051-1059
31. Ganji S.H., Tavintharan S., Zhu D., Xing Y., Kamanna V.S., and Kashyap M.L. Niacin non-competitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 45 (2004) 1835-1845
32. Carlson L.A., and Oro L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand 172 (1962) 641-645
33. Carlson L.A. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 173 (1963) 719-722
34. Carlson L.A., and Riccardi G. Clinician's Manual on Diabetic Dyslipidemia (2004), Science Press, London
35. Blum C.B., Levy R.I., Eisenberg S., Hall M., Goebel R.H., and Berman M. High density lipoprotein metabolism in man. J Clin Invest 60 (1977) 795-807
36. Shepherd J., Packard C.J., Patsch J.R., Gotto M., and Taunton O.D. Effect of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 63 (1979) 858-867
37. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin decreases removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 17 (1997) 2020-2028
38. Acton S., Riggoti A., Landschutz K.T., Xu S., Hobbs H.H., and Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 (1996) 518-520
39. Martinez L.O., Jacquet S., Esteve J.P., Rolland C., Cabezon E., Champagne E., Pineau T., Georgeand V., Walker J.E., Terce F., et al. Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421 (2003) 75-79
40. Zhang L.H., Meyers C.D., Kamanna V.S., and Kashyap M.L. Niacin inhibits β chain ATP synthase cell surface expression in HepG2 cells: mechanistic implications for raising HDL [abstract]. Arterioscler Thromb Vasc Biol 26 (2006) E-53
41. Jacobson E.L., and Jacobson M.K. A biomarker for the assessment of niacin nutriture as a potential preventive factor in carcinogenesis. J Intern Med 233 (1993) 59-62
42. + precursors, nicotinic acid and nicotinamide upregulate glyceraldehydes-3-phosphate dehydrogenase and glucose-6-phosphate dehydrogenase mRNA in Jurkat cells. Biochem Biophys Res Commun 255 (1999) 133-136
43. Ganji S.H., Qin S., Liu Y., Kamanna V.S., and Kashyap M.L. Niacin inhibits LDL oxidation and redox-sensitive VCAM-1 and MCP-1 expression in human aortic endothelial cells. [abstract]. Arterioscler Thromb Vasc Biol 24 (2004) E-125
44. Poynten A.M., Gan S.K., Kriketos A.D., O'Sullivan A., Kelly J.J., Ellis B.A., Chisholm D.J., and Campbell L.V. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52 (2003) 699-704
45. Yu X.X., Murray S.F., Pandey S.K., Booten S.L., Bao D., Song X.Z., Kelly S., Chen S., McKay R., Monia B.P., and Bhanot S. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42 (2005) 362-371
46. 2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38 (1989) 263-274
47. Benyo Z., Gille A., Bennett C.L., Clausen B.E., and Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol 70 (2006) 1844-1849
48. 2 in response to nicotinic acid. J Invest Dermatol 126 (2006) 2637-2646
49. 2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis 192 (2007) 253-258
50. Benyo Z., Gille A., Kero J., Csiky M., Suchankova M.C., Nusing R.M., Moers A., Pfeffer K., and Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115 (2005) 3634-3640
51. 2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 103 (2006) 6682-6687
52. Taggart A.K., Kero J., Gan X., Cai T., Cheng K., Ippolito M., Ren N., Kaplan R., Wu K., Wu T.J., et al. (D)-β-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 280 (2005) 26649-26652
53. Soudijn W., van Wijngaarden I., and Ijzerman A.P. Nicotinic acid receptor subtypes and their ligands. Med Res Rev 27 (2007) 417-433
54. Van Herk T., Brussee J., van den Nieuwendijk A.M.C.H., van der Klein P.A.M., Ijzerman A.P., Stannek C., Burmeister A., and Lorenzen A. Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem 46 (2003) 3945-3951
55. Seki K., Isegawa J., Fukuda M., and Ohki M. Studies on hypolipidemic agents. II. Synthesis and pharmacological properties of alkylpyrazol derivatives. Chem Pharm Bull (Tokyo) 32 (1984) 1568-1577
56. Arena Pharmaceuticals, Inc., San Diego, CA, USA. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases. WO2005/011677A1.
57. Arena Pharmaceuticals, Inc., San Diego, CA, USA. Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof. WO2005/044816A1.
58. Arena Pharmaceuticals, Inc., San Diego, CA, USA. 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof. WO2005/051937A2.
59. SmithKline Beecham Corporation, London, UK. 2-Substituted benzoic acid derivatives as HM74A receptor agonists. WO2005/016870A1.
60. SmithKline Beecham Corporation, London UK. Anthranilioc acid derivatives and their use as activators of the HM74A receptor. WO2005/016867A2.